To mark the 20th anniversary of NCRIS, we’re pleased to share a newly released video celebrating the program’s impact.
The video features NCRIS “super user” Prof. James Hudson, who highlights the strong collaboration between multiple NCRIS providers (including Phenomics Australia) and the value of Australia’s national research infrastructure ecosystem.
A strong example of how multiple NCRIS facilities collaborate to drive research translation and innovation in Australia with a real-world impact.
NCRIS: Celebrating 20 Years of Research Support and Innovation
In this video, Prof. James Hudson, reflects on how cardiac bioengineering research, supported by several NCRIS providers, has translated into two spin‑out companies that he co-founded: Dynomics, which is developing advanced human cardiac tissue platforms that enable more accurate drug screening and disease modelling, and Ibnova Therapeutics, which is advancing cardiac patch technologies designed to repair damaged heart tissue.
That translation journey has been supported throughout by infrastructure and expertise made possible by the Australian Government’s National Collaborative Research Infrastructure Strategy (NCRIS). Several members of the NCRIS health group, including Therapeutic Innovation Australia, The Australian National Fabrication Facility (ANFF), Phenomics Australia and Microscopy Australia, played a key role in helping these platforms along the journey from fundamental research to commercial product.
With Phenomics Australia’s support of the iPSC Derivation & Gene Editing Facility Node at Murdoch Children Research Institute (MCRI) and the Pipeline Accelerator scheme, they have accelerated the way treatments are identified and tested for heart-related disease.
“The support of the Voucher scheme enabled us to generate a novel line, which enabled us to perform lineage tracing of stromal cells in human cardiac organoids for the first time. This provided really important information to show that these cells resemble native cardiac cells. We hope to now extend these findings and discover new therapeutics targeting the stromal cells for heart failure.” Prof. James Hudson said.
